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Dual bioresponsive antibiotic and quorum sensing
inhibitor combination nanoparticles for treatment
of Pseudomonas aeruginosa bioﬁlms in vitro and
ex vivo†
Nishant Singh,‡a Manuel Romero,‡b Alessandra Travanut,a Patricia F. Monteiro, a
Elena Jordana-Lluch, §c Kim R. Hardie, c Paul Williams, c
Morgan R. Alexander a and Cameron Alexander *a
Many debilitating infections result from persistent microbial bioﬁlms that do not respond to conventional
antibiotic regimens. A potential method to treat such chronic infections is to combine agents which inter-
fere with bacterial bioﬁlm development together with an antibiotic in a single formulation. Here, we
explore the use of a new bioresponsive polymer formulation derived from speciﬁcally modiﬁed alginate
nanoparticles (NPs) in order to deliver ciproﬂoxacin (CIP) in combination with the quorum sensing inhibi-
tor (QSI) 3-amino-7-chloro-2-nonylquinazolin-4(3H)-one (ACNQ) to mature Pseudomonas aeruginosa
bioﬁlms. The alginate NPs were engineered to incorporate a pH-responsive linker between the polysac-
charide backbone and the QSI, and to encapsulate CIP via charge–charge interactions of the positively-
charged drug with the carboxyl residues of the alginate matrix. In this way, a dual-action release of anti-
biotic and QSI was designed for the low-pH regions of a bioﬁlm, involving cleavage of the QSI-linker to
the alginate matrix and reduced charge–charge interactions between CIP and the polysaccharide as the
alginate carboxyl side-chains protonated. When tested in a bioﬁlm model the concomitant release of
CIP + QSI from the pH-responsive nanoparticles signiﬁcantly reduced the viability of the bioﬁlm com-
pared with CIP treatment alone. In addition, the alginate NPs were shown to penetrate deeply into
P. aeruginosa bioﬁlms, which we attribute in part to the charges of the NPs and the release of the QSI
agent. Finally, we tested the formulation in both a 2D keratinocyte and a 3D ex vivo skin infection model.
The dual-action bio-responsive QSI and CIP release nanoparticles eﬀectively cleared the infection in the
latter, suggesting considerable promise for combination therapeutics which prevent bioﬁlm formation as
well as eﬀectively killing mature P. aeruginosa bioﬁlms.
Introduction
The increasing problems of multi-antibiotic resistance
urgently require alternative therapeutic options.1–3 One of the
main issues associated with indiscriminate antibiotic use is
the activation of defence mechanisms in pathogens,4 and as a
survival strategy, bacteria form biofilms.5 These are surface-
associated multicellular communities embedded in a self-gen-
erated extracellular matrix (ECM).6 The latter is composed of
polysaccharides, proteins and extracellular DNA (eDNA), and is
both heterogeneous in composition and architecture, as well
as resistant to penetration by antimicrobial agents.7 Upon
administration, most antibiotics kill the more susceptible
planktonic bacterial cells, leaving behind the intrinsically anti-
biotic tolerant biofilm embedded bacteria. The tolerance of
biofilms to antimicrobial agents generally is multifactorial
involving physical, physiological and intrinsic genetic determi-
nants whereas antibiotic resistance is a consequence of
mutations and the acquisition of antibiotic resistance genes
via horizontal gene transfer.8 Biofilms are also refractory to
clearance by the host immune system and so elicit a number
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of major clinical challenges, such as chronic inflammation,
impaired wound healing and systemic spread of chronic infec-
tions.9 Novel therapeutic strategies are thus urgently needed to
combat the threat of biofilm-centred infections.10–17
One of the most promising approaches is the combined-use
of antibiotics with adjuvants that do not aﬀect the pathways
essential for the bacterial growth and viability, and as a conse-
quence are less likely to select for resistance. Such agents have
various modes of action including (i) increasing bacterial cell
membrane permeability, (ii) impairing biofilm formation, and/
or the production of virulence factors and antibiotic resistance
elements, (iii) blocking antibiotic eﬄux pumps and (iv) chan-
ging phenotype from the biofilm to the planktonic state
through biofilm dispersal. Since bacterial communities co-
ordinate their pathogenic activities including biofilm develop-
ment through cell–cell communication (quorum sensing,
QS)5,18 using small diﬀusible signal molecules, disruption of
QS interferes with biofilm formation and maturation.19–23
However, while there are combination formulations in the
clinic which use antibiotics and β-lactamase inhibitors (e.g.
Tazocin®, Unasyn® Augmentin®), none to date have utilised
QS inhibitors (QSIs) as biofilm disrupting agents. Several QS
and QSI control and release systems have however been
described, including molecularly imprinted polymers which
bind the QS agents to suppress bacterial biofilm formation,
and peptide mimetics which disrupt biofilms of several bac-
terial strains.24–29
Here we set out to prepare a new antimicrobial biofilm for-
mulation which would have the following attributes, (i) QS
inhibition, (ii) broad spectrum antibiotic activity, (iii) good
biofilm penetration, and (iv) good tissue compatibility with
low cytoxicity. We selected the clinically important bacterium
Pseudomonas aeruginosa as the model organism, as this patho-
gen is responsible for more than 30% of hospital-acquired
infections and causes chronic biofilm-centred infections in
diverse body sites. This organism is also intrinsically resistant
to many antibiotics and a member of the ESKAPE group of
multi-antibiotic resistant bacterial pathogens.30 For the QS
inhibitor (QSI), we selected 3-amino-7-chloro-2-nonylquinazo-
lin-4(3H)-one (ACNQ), a potent inhibitor of the pseudomonas
quinolone QS system which targets the PqsR receptor. ACNQ
inhibits virulence factor production and biofilm development
and in particular reduces the production of matrix com-
ponents including eDNA and rhamnolipids.31 The second
component was ciprofloxacin, (CIP), a fluoroquinolone anti-
biotic with broad spectrum activity but also a drug to which
bacterial pathogens including P. aeruginosa have acquired re-
sistance.32 In order to penetrate a dense biofilm matrix, we
chose to encapsulate the antibiotic and conjugate the QSI
within in situ-formed sodium alginate nanoparticles. These
carry a net negative charge at the pH values likely to be
encountered in many bacterial biofilms. In addition, alginate
oligosaccharides have been reported to disrupt biofilm for-
mation and maturation and potentiate antibiotic action
against P. aeruginosa.33 We thus anticipated that the alginate
nanoparticles might penetrate further into the biofilm since
the ECM contains polyanion-containing exopolysaccharides
and eDNA34 as well as the negatively charged P. aeruginosa cell
envelope,35 compared with ACNQ (weakly basic) and CIP
(zwitterionic, but with a net positive charge at pH 7.4). In
addition, alginates are already widely used in oral formu-
lations, have a proven safety profile, are readily available, and
can be derivatised further due to their multiple carboxyl
residues.36
The combined formulation thus consisted of alginate-based
nanoparticles (NPs), containing CIP encapsulated by charge–
charge interactions during a nanoprecipitation process, with
ACNQ attached via a pH-responsive hydrazine linker, and of a
size range (150–200 nm) similar to those of Pseudomonas bac-
teriophages.37 We then tested these formulations as synergistic
adjuvant-drug therapeutics in infection models consisting of
pre-established biofilms of P. aeruginosa PAO1-Nottingham
subline (PAO1-N) of ≥100 µm thickness in vitro and in both 2D
and 3D skin infection models. The formulation and anti-infec-
tive action is shown schematically in Fig. 1.
Materials and methods
Experimental
Materials. 2-Ethynylbenzaldehyde, 2-chloro-4,6-dimethoxy-
1,3,5-triazine (CDMT), and trimethylamine (TEA) were pur-
chased from Acros Organics. 4-Methylmorpholine (NMM),
6-amino fluorescein, ciprofloxacin, 11-azido-3,6,9-trioxaunde-
can-1-amine, blue fluorescent polystyrene-NH2 nanoparticles
(λex ∼360 nm; λem ∼420 nm, d-50 nm), and deuterated chloro-
form (CDCl3), water (D2O), and dimethyl sulfoxide (DMSO-D6)
were purchased from Sigma-Aldrich. Pronova UPVLVG Alginate
was bought from Novamatrix. Dialysis tubes (10 000 Da, 3500
Da and 2000 Da MWCO) and Red fluorescent polystyrene-NH2
nanoparticles (λex ∼580 nm; λem ∼605 nm, d-200 nm) were pur-
chased from ThermoFisher Scientific. All other analytical and
synthesis grade solvents were purchased from ThermoFisher
Scientific.
Instrumentation. 1H and 13C NMR spectra were obtained
using a Bruker DPX400 UltraShieldTM spectrometer at
400 MHz (1H and 13C). An AV(III) 500 NMR spectrometer with
carbon–hydrogen Cryoprobe at 500 MHz was used to acquire
13C NMR of the polymers ALGALD and ALGQSI. The FTIR
spectra of the lyophilized alginate polymer samples (N3-PEG3-
ALG, ALGALD and ALGQSI) were obtained using 64 scans with
CARY 630 FTIR spectroscopic suite by Agilent Technologies.
Nanoparticle morphology was analysed using a Tecnai G2 (FEI,
Oregon USA) transmission electron microscope (TEM). The
size and zeta potential of NPs were measured at 25 °C by
dynamic light scattering (DLS, Zetasizer Nano ZS90, Malvern
Instruments Ltd, UK). Drug encapsulation and release experi-
ments were quantified using a Cary 50 Bio UV spectrometer.
Confocal laser scanning microscopy was carried out using a
LSM 700 microscope (Carl Zeiss, Germany) and 96-well plates
were imaged using TECAN Genios Pro reader (Tecan, UK).
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Synthesis
(Z)-7-Chloro-3-((2-ethynylbenzylidene)amino)-2-nonylquina-
zolin-4(3H)-one. To a solution of 2-ethynylbenzaldehyde
(50 mg, 4 equiv., 0.384 mmol) and triethylamine (100 µL) in
dry methanol (20 mL), was added ACNQ, synthesized as
described before31 (30 mg, 1 equiv., 0.096 mmol) under an
argon atmosphere and the mixture was stirred at 50 °C for
72 h. Methanol was then evaporated under vacuum. The
obtained reaction mixture was purified by column chromato-
graphy to obtain the pure product as an oﬀ-white solid in 80%
yield (eluent: MeOH/triethylamine/CHCl3-4/1/95). ESI-pre-
dicted mass – 433.19, Mass found+ H+-434.2006.
1H NMR (CDCl3, 400 MHz, 25 °C), δ (ppm) 1H (9.55, s), 2H
(8.26–8.24, d), 1H (7.72–7.73, d), 1H (7.67–7.62, dd), 2H,
(7.60–7.50, p), 1H (7.44–7.41, dd), 1H (3.43, s), 2H (2.98–2.94,
t), 2H (1.86–1.79, p), 2H (1.59, s), 2H (1.45–1.40, s), 8H
(1.40–1.25, m), 3H (0.90–0.57, t). 13C NMR (101 MHz, CDCl3)
δ 165.1, 158.24, 158.2, 147.4, 140.4, 134.3, 133.4, 131.9, 129.2,
128.8, 126.9, 126.7, 126.1, 124.4, 119.9, 84.0, 79.9, 35.2, 31.8,
29.4, 29.3, 29.3, 29.2, 26.7, 22.6, 14.1.
11-Azido-3,6,9-trioxaundecanamido-alginate (N3-TEG-ALG).
Sodium alginate (1 equiv., 400 mg = 2.08 mmol of –COOH) was
dissolved as a 2% alginate solution in a 12 mL : 8 mL – water :
acetonitrile mixture at 55 °C. 11-Azido-3,6,9-trioxaundecan-1-
amine (1 equiv., 2.08 mmol, 453 mg) was then added to the
mixture along with the coupling reagents 2-chloro-4,6-
dimethoxy-1,3,5-triazine (CDMT, 0.5 equiv., 1.04 mmol,
180 mg) and 4-methylmorpholine (NMM, 1 equiv., 2.08 mmol,
224 μl). The mixture was stirred at 55 °C for 16 h after which
the solvent was removed under reduced pressure. The resulting
solid was dissolved in water and filtered through cyano-modi-
fied silica gel to remove insoluble precipitates. The obtained
solution was then dialyzed against a 10 000 MWCO dialysis
membrane for 2 days with DI water. The solution was then lyo-
philized to obtain the purified polymer. 1H NMR (D2O,
400 MHz, 25 °C), δ (ppm)-6.57 (s, Alg-CO–NH–CH2CH2–
(OCH2CH2)3–N3), 5.10–4.90 (m, alginate), 4.60–3.80 (alginate,
m), 3.80–3.50 (–(OCH2–CH2)3–O, 12H, m), 3.50–3.35 (Alg-CO–
NH–CH2–CH2–O–, 2H, t), 3.20–3.10 (–OCH2–CH2–N3, 2H, t). IR
(wavenumber, cm−1) – 1600 (CO–NH amide stretch), 2100 (N3
(azide) stretch), 2879, 2918 (CH stretch), 3278 (–COOH stretch).
Aldehyde-functional alginate and QSI-alginate conjugate
(ALGALD or ALGQSI). 11-Azido-3,6,9-trioxaundecanamido-algi-
nate (N3-TEG-ALG, 100 mg) was dissolved in a solution of
water : methanol 1 : 1 (5 mL) at 55 °C. To this solution were
added tris[(1-benzyl 1H-1,2,3-triazol-4-yl) methyl]amine (TBTA,
0.2 equiv., 50 mg), triethylamine (0.25 equiv., typically 15 μl),
and copper(I)-iodide (0.25 equiv., 5 mg) as coupling agents.
Then 0.51 mmol of 2-ethynylbenzaldehyde (for ALGALD) or (Z)-
7-chloro-3-((2-ethynylbenzylidene)amino)-2-nonylquinazolin-4
(3H)-one (for ALGQSI) was added and the mixture was stirred at
55 °C overnight. The solvent was removed under reduced
pressure and the oily product was resuspended in 5 mL of
water and dialyzed. The resulting solution was then dialyzed
using a 10 000 MWCO dialysis membrane in phosphate buﬀer
pH 7.4 to purify further the polymer, which was then recovered
after lyophilisation.
ALGALD –
1H NMR (D2O, 400 MHz, 25 °C), δ (ppm) 9.88
(–CHO, 1H, s), 8.44 (triazole, 1H, s), 8.00–7.66 (aromatic from
Fig. 1 Schematic of combined polymer, QSI and antibiotic nanoparticle formulation (A, B) and activity against P. aeruginosa bioﬁlms in vitro (C, D,
E). Structures of components are shown in (A) with TEM micrographs in (B) In (C) viable P. aeruginosa are labelled green following treatment with
blank NPs; while in (D) non-viable cells are labelled red following incubation with ALGQSI + CIP. Eﬃcacy in an ex vivo infected skin model is shown
in (E).
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benzaldehyde, 4H, m), 7.47 (amide, 1H, m), 5.10–4.90 (algi-
nate, 2H, m), 4.79 (H2O), 4.25–3.50 (alginate, m), 3.50–2.75
(Alg-CO–NH–CH2–CH2–(O–CH2–CH2)3–N-triazole) oliethyl-
eneglycol (PEG3) (linker, m, 16H, m). 13C-(DMF, 120 MHz,
25 °C), δ (ppm)-195.4 (–CHO), 175.9 (–COOH-alginate), 175.4
(Alg-CONH-PEG3-), 149.9 (–N–CvC–NvN-triazole ring), 149.8
(–C–CHO-aromatic ring), 135, 134, 133, 130, 129.6 (aromatic
Cs from benzaldehyde), 129.5 (N–CvC–NvN-triazole ring),
100.9, 100.6, 100.1, 99.8, (Alginate-C–O–C), 80.0, 77.2, 76.1,
72.0 (Alginate-C–OH), 68.5, 67.5 (Alg-CO–NH–CH2CH2–O–
(CH2CH2)2–O–CH2–CH2-triazole), 67.0, 64.8, 62.4, 50.3, 46.6,
38.7 (Alg-CO–NH–CH2–CH2–(O–CH2CH2)2–O–CH2–CH2-tri-
azole-). IR (wavenumber, cm−1) – 1600 (CONH amide carbonyl
stretch), 1686 (–CHO carbonyl stretch), 2855 (aromatic CHO
stretch), 2918 (triazole ring), 3062 (CH-alkane stretch from oli-
goethyl PEG3 linker), 3278 (–COOH stretch).
ALGQSI –
1H NMR (D2O/DMSO-d6-90/10, 400 MHz, 70 °C),
δ (ppm)-8.60–7.40 (aromatic and hydrazone protons of ACNQ-
triazole conjugate, m), 5.30–5.00 (alginate, 2H, m), 4.75–4.00
(alginate, m), 4.71 (HDO), 4.20, 3.90 and 3.60–3.90 (Alg-
CONH–CH2–CH2–(O–CH2–CH2)3-triazole-, m), 2.50 (DMSO),
1.75–1.50 (m, –(CH2)9–CH3 alkyl chain of ACNQ).
13C-(DMF,
120 MHz, 25 °C), δ (ppm) 161.0 (Alg-CONH-PEG3-), 145.4 (–N–
CvO-ACNQ drug), 140.1 (–N–CvC–NvN-triazole ring), 137.7
(C9–C(–N–)–NvN-ACNQ drug), 134.0 (tert-aromatic unsubsti-
tuted Cs of ACNQ QSI chlorinated ring), 129.8–129.1 (CvC
tert-aromatic), 127.3 (–N–NHvC–, hydrazone bond), 125.3
(aromatic C–Cl, ACNQ QSI drug), 121.2 (quart-C–N, aromatic–
Cl ring ACNQ), 74.8, 71.8, 71.6, 70 (–C–O–C, alginate),
64.9–64.8 (–C–CO–, alginate), 54.1 (Alginate-C–OH), 48.3,
46.5 (Alg-CO–NH–CH2CH2–O–(CH2CH2)2–O–CH2–CH2-tri-
azole), 32.7–28.2–26.5 (Alg-CO–NH–CH2–CH2–(O–CH2CH2)2–
O–CH2–CH2-triazole-), 23.5 (CH3–(CH2)7–CH2-ACNQ QSI drug),
14.7 (CH3–(CH2)7–CH2-ACNQ), 9.2 (CH3–(CH2)7–CH2-ACNQ).
IR (wavenumber, cm−1) 693, 713, 827 (C–Cl, heteroatom
stretch from ACNQ), 1051, 1215 (C–N aliphatic stretch from
ACNQ), 1510 (CvN hydrazone stretch), 2918 (triazole ring),
3060 (CH-alkane stretch from alkyl chain of ACNQ and oli-
goethyl PEG3 linker), 3142 (aromatic stretch from ACNQ and
aromtic linker), 3278 (–COOH stretch).
Fluorescein-labelled N3-TEG-ALG. 6-Aminofluorescein
(1 equiv.) was added to a stirred solution of CDMT (0.2 equi.),
NMM (1 equiv.) and N3-PEG3-ALG (1 equiv.) in H2O/aceto-
nitrile (3/2) mixture at 55 °C. The reaction mixture was allowed
to stir overnight. Acetonitrile from the reaction mixture was
removed by drying in vacuo followed by dilution of the product
in DI water and dialysis against 10 K MWCO dialysis mem-
brane for 2 days. The obtained solution was lyophilised and
used without further purification.
Carboxyl-functional NPs from amino-functional polymer
latex beads. Commercially available amino-functional latex
polystyrene beads of diameter 50 or 200 nm (obtained from
Sigma-Aldrich and ThermoFisher Scientific respectively) were
suspended in water (2 mL) along with trimethylamine (15 µL)
and N-hydroxysulfosuccinimide sodium salt (20 mg). The
resulting solution was left to stir at 0 °C for 1 hour followed by
addition of succinic anhydride (20 mg). The reaction mixture
was allowed to stir overnight at room temperature before dialy-
sis against a 2 kDa membrane to remove the excess of
reagents. The diameter and zeta potentials of the obtained
NPs were measured to confirm the successful functionalisation
by succinic acid.
Determination of N3 functional groups in N3-TEG-ALG
The ERETIC method (Electronic REference To access In vivo
Concentrations)38 was used in which 4 mg of N3-TEG-ALG was
dissolved in 600 µL of D2O to which 0.275 mg of hydroquinone
dissolved in 100 µL of D2O was added. The peak of hydro-
quinone at 6.7 ppm (4H) was used to calculate the concen-
tration of N3-PEG3 groups in the N3-PEG3-ALG polymer.
Protocol for nanoparticle (NP) formation
The NPs were prepared by a one-step in situ nanoprecipitation
process. Briefly, the sodium alginate polymers (10 mg) were
dissolved in PBS (10 mL) containing Tween 20 by sonication
and added dropwise to a solution of CIP (10 mg) dissolved in
0.1 N HCl solution (0.1 mL). This solution was stirred over-
night at RT. The solution obtained was dialysed against PBS
for 72 hours to remove the free drug molecules. The dialysate
was then freeze-dried and stored at 4 °C before use. The lyophi-
lised NPs were equilibrated at room temperature and re-sus-
pended in Tween 20 stabilised PBS (10 mL) before use. NPs
without CIP were prepared by dissolving the 10 mg of polymer
in 10 mL of 0.1 N HCl in buﬀer by sonication, followed by stir-
ring overnight at RT.
Morphology, particle size, and zeta potential of NPs
The morphologies of the NPs were characterized by trans-
mission electron microscopy (TEM; Tecnai G2, FEI, Oregon
USA). The samples for TEM were prepared by adding dropwise
the NP solution (1 mg mL−1) onto the copper grid followed by
drying for 4 hours before performing the microscopy. The par-
ticle sizes and zeta potentials of the NPs (1 mg mL−1) were
determined using a Zetasizer Nano ZS90, Malvern Instruments
Ltd, UK.
Drug loading and pH-dependent release from the NPs
The amount of CIP in the NPs was quantified using a Cary 50
Bio UV spectrometer. Briefly, the amount of encapsulated CIP
was obtained by dissolving diﬀerent volumes of CIP-contain-
ing NPs in triplicate samples (1 µL, 2 µL, 3 µL, 4 µL, 5 µL) in
0.1 N HCl solution (∼1 mL) to release all the encapsulated CIP
followed by dilution in PBS (total final volume-11 mL). The
final concentration of CIP in the NPs was obtained (0.7
mg CIP per mL for ALGALDCIP and 0.8 mg CIP per mL for
ALGQSICIP) by comparing the UV peak intensities with the cali-
bration curve of CIP (λmax = 275 nm). The amount of ACNQ in
the NPs was estimated by directly correlating the complete
consumption of azide groups in N3-PEG3-ALG (following
2100 cm−1 peak corresponding to azide(N3) by IR) to the con-
centration of added QSI-alkyne molecule after the click reac-
tion. The amount of ACNQ drug was considered the same as
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the amount of N3 groups previously present in ALG-PEG3-N3 as
determined by the ERETIC NMR technique.
For pH-responsive release, the release profiles of CIP (λmax =
275 nm) and ACNQ (λmax = 240 nm) from the NPs were studied
using UV-VIS spectroscopy in pH 7.4 PBS buﬀer or pH 6.0
citric acid buﬀer. Typically, 2 mL of NPs solution (1.0 mg
mL−1) were placed in a dialysis bag (MWCO = 10 kDa), which
was then immersed in 5 mL of release medium at diﬀerent pH
values at 37 °C and with constant shaking at 100 rpm. At the
predetermined time points, 3 mL of medium was collected
and replaced by 3 mL of fresh buﬀer.
Bacterial growth inhibition
To evaluate the growth inhibitory activity of alginate-CIP conju-
gates, free or encapsulated CIP was tested against P. aeruginosa
PAO1-N cultures at concentrations 0.01, 0.05, 0.1, 0.2, 0.5 and
1 µg mL−1. Bacteria were grown overnight in Luria broth (LB)
at 37 °C. The next day the optical density (OD600 nm) of the
culture was adjusted to 0.01 in FAB39 medium containing
10 mM glucose and 200 µL aliquots supplemented with CIP
were loaded into the wells of a 96-well plate. As controls,
medium only and wells containing NPs without ciprofloxacin
were employed. Bacterial growth was monitored for 24 h at
37 °C in a 96-well plate TECAN Genios Pro spectrophotometer
(Tecan, UK). The minimum inhibitory concentration (MIC)
was defined as the antibiotic concentration where no visible
bacterial growth was observed or OD600 nm was <10% com-
pared with the untreated control after 24 h of antibiotic
exposure.
Biofilm viability and penetration assays
Mature pre-established PAO1-N biofilms were grown to assess
the eﬀects of co-delivered CIP and ACNQ on biofilm viability.
For these assays, PAO1-N biofilms were grown on round glass
coverslips (8 mm, #1.5 thickness) under flow conditions
(20 rpm) in FAB containing 10 mM glucose medium inocu-
lated with a diluted (OD600 nm = 0.01) bacterial suspension
from overnight cultures in LB. Biofilms were cultivated at
30 °C for 3 days with medium replacement every day. Biofilms
were washed in PBS to remove loosely attached cells, and incu-
bated for a further 24 h in fresh FAB medium supplemented
with various treatments. These included free CIP and/or ACNQ
as well as the NPs: ALGAld (empty NPs), ALGQSI, ALGALDCIP
and ALGQSICIP. With final concentrations of CIP and ACNQ of
60 µg mL−1 (300× MIC) and 4 µg mL−1 respectively. Biofilms
exposed to each treatment were washed in PBS and the viabil-
ities of the attached cells were evaluated using the LIVE/
DEAD® BacLight™ Bacterial Viability kit (Molecular Probes,
Life Technologies) according to the manufacturer’s instruc-
tions. Following staining, coverslips were rinsed with sterile
water and imaged using a LSM 700 laser scanning confocal
microscope (CLSM) (Carl Zeiss, Germany). Viable and non-
viable biomass quantification from image stacks of biofilms
was done with Comstat2 software39 (http://www.comstat.dk).
Live/dead ratios were established for each treatment and com-
pared with untreated controls. Five independent assays were
carried out in triplicate.
To ascertain that the reduced viability of the biofilms
exposed to combined therapy was retained at diﬀerent levels of
exposure, a dose–response validation was carried out using
diﬀerent concentrations of CIP (5, 20 and 60 µg mL−1 = 25×,
100× and 300× MIC respectively) while retaining the QSI con-
centration constant at 4 µg mL−1. The biofilm viability was
compared with that of free CIP treatment and an untreated
control.
To evaluate NP diﬀusion through the biofilm matrix,
ALGALD and ALGQSI conjugates were labelled with fluorescein
and tested against 3-day old PAO1-N biofilms. After 1, 2 and
24 h of incubation with NPs, biofilm samples were collected
and stained with Syto64 fluorescent dye prior to CLSM image
acquisition to simultaneously detect bacterial cells (red fluo-
rescence) and NPs (green fluorescence). NP diﬀusion was
determined by quantifying the fluorescein signal associated
with each image stack and relating it to the biomass at
diﬀerent biofilm depths. Moreover, to relate biofilm pene-
tration of alginate conjugates with other commercially avail-
able fluorescent NPs, the diﬀusion of blue fluorescent 50 nm
polystyrene beads and red fluorescent 200 nm polystyrene
beads carrying positive or negative zeta potentials were also
tested in biofilms stained with Syto64 and Syto9 dyes
respectively.
2D keratinocyte infection model
HaCat cells. Immortalised keratinocytes (HaCat) were used
as a substrate for the 2D infection model. HaCat cells were
expanded in T75 flasks (Corning), in RPMI-1460 medium sup-
plemented with 10% heat inactivated fetal bovine serum (FBS),
2 mM L-glutamine and 1% penicillin (10 000 units)/streptomy-
cin (10 mg mL−1) until the monolayer was 80–85% confluent.
Cells were trypsinised using trypsin/EDTA and seeded at
45 000 cells per cm2 in an 8 well µ-slide Ibitreat chamber
(Ibidi, Germany). When 90–100% confluent, cells were washed
three times with Dulbecco’s phosphate-buﬀered saline (DPBS).
Prior to infection, HaCat cells were stained using CellTracker
Green CMFDA (Thermofisher), following the manufacturer’s
instructions.
Biofilm formation. An overnight culture of PAO1-N carrying
the plasmid pME6032-mCherry in LB liquid medium sup-
plemented with 125 µg mL−1 of tetracycline was diluted 1 in 5
and incubated (37 °C, 200 rpm) until the OD600 nm reached
0.8–1. After washing with PBS, the culture was normalised in
RPMI-1460 supplemented with 10% FBS and 2 mM
L-glutamine to an OD600 nm = 0.01, further diluted 1 in 100 000
and 150 µL were added to each well containing confluent
HaCat cells. ALGQSI NPs containing 4 µg mL
−1 of QSI or
ALGALD (empty NPs) were added at a final concentration
300 µg mL−1. Infected cells were incubated at 37 °C, with 5%
CO2 and 95% humidity for 20 h prior to imaging using CLSM.
Image analysis. Biomass, average thickness and surface area
of 8–10 image stacks of 20 h PAO1-N biofilms growing on
HaCat cells monolayers were quantified using COMSTAT2 soft-
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ware employing automatic thresholding (Otsu’s method) and
without connected volume filtering.
3D skin infection model
Pig skin preparation and infection. Pig ears (obtained from
an abattoir) were cleansed with sterile distilled water and depi-
lated with a dry razor before soaking with antibacterial soap
containing chlorhexidine gluconate 4.0% w/v (Hibiscrub,
Boots) for 3 min. After removing the soap with sterile water,
skin sections at the front and back of the ear were cut away
from the subcutaneous cartilage. The sections were frozen at
−20 °C until required. A biopsy punch (7 mm) was used to
remove skin plugs from freshly thawed skin samples. The skin
plugs were immersed in ethanol for 20 min, then washed with
PBS (×2) and immersed into 100× Antibiotic Antimycotic solu-
tion for 10 minutes and washed with PBS (×3). The excess of
water from skin plugs was removed with filter paper and the
plugs were transferred to a 96-well plate containing 200 µL of
soft agar. The skin was then infected with 10 µL of PAO1-N
pME6032-mCherry suspension (OD600 nm 0.05) in PBS and
incubated at 37 °C, with 5% of CO2 and 95% humidity for
24 h. 15 µL of CIP 1 mg mL−1, ALGQSI, ALGQSICIP (containing
1 mg mL−1 of CIP), ALGALD or ALGALDCIP (containing 1 mg
mL−1 of CIP) were added to the infected skin plugs in triplicate
and incubated for further 24 h.
Bacterial cell viable counts. Skin plugs were transferred to
1 mL of PBS and vortexed for 20 s to remove loosely attached
bacteria. The samples were transferred for processing to
FastPrep tubes containing 1 mL of PBS and six ceramic beads
(2.8 mm) and were homogenised (FastPrep, MP Biomedicals),
using the built-in ‘skin’ set-up. The supernatants were serially
diluted 10-fold (10−1 to 10−8) and each dilution plated in tripli-
cate onto LB agar plates containing 125 µg mL−1 of tetra-
cycline. The plates were incubated at 37 °C for 24 h.
Data analysis. GraphPad Prism 8 software was used for
graphical representation and statistical analysis. Quantitative
variables were compared using Student’s t test. A p-value <0.05
was considered statistically significant.
Results and discussion
Polymer synthesis and characterisation
The design principles of the combination therapeutic were
firstly that it needed to be derived from a simple, readily
accessible polymer already used in human clinical appli-
cations. Secondly, the chemistries should enable a QSI to be
attached via a pH-responsive linker and an antibiotic to be
encapsulated. Finally, the whole system was required to self-
assemble into lightly negatively-charged nanoparticles (NPs)
in order to penetrate dense bacterial biofilms. Accordingly,
we chose sodium alginates as the ‘platform’ material and
modified the polymer with functionalities which enabled
active agents to be incorporated via Schiﬀ base linkages for
in situ release in the acidic environment of a biofilm. We
selected the QSI, 3-amino-7-chloro-2-nonylquinazolin-4(3H)-
one (ACNQ) (Ilangovan et al. 2013)31,40, and utilised a triethyl-
eneglycol spacer to append it to the alginate to ensure this
hydrophobic drug was accessible to the aqueous environment
when formulated. Finally, we opted for ciprofloxacin (CIP) as
the antibiotic, as its positive charge at ambient pH values
facilitated association with the alginate carboxylates and
induced self-assembly of the system into NPs of sizes
(150–200 nm) similar to those of Pseudomonas bacterio-
phages.37 The synthetic scheme for the construction of the
dual bioresponsive combination therapeutic nanoparticles is
shown in Scheme 1.
The synthesis started with Schiﬀ base formation between
2-ethynylbenzaldehyde and ACNQ to form (Z)-7-chloro-3-((2-
ethynylbenzylidene)amino)-2-nonylquinazolin-4(3H)-one in
∼80% yield. In parallel, CDMT/NMM based amide coupling
was used to attach azide groups via a triethyleneglycol linker
to the alginate backbone to obtain N3-TEG-ALG (Scheme 1).
The derivatisation of the alginate backbone was confirmed
by 1H NMR and IR, with the presence of the azide groups
apparent in FTIR spectra at 2100 cm−1. The ERETIC method
(Electronic REference To access In vivo Concentrations)38
was used to estimate the amount of free azide groups in N3-
TEG-ALG (∼0.1 µmol/1 mg). For the next steps, the well-
established Cu-catalysed azide–alkyne click reactions were
used to attach (Z)-7-chloro-3-((2-ethynylbenzylidene)amino)-
2-nonylquinazolin-4(3H)-one with N3-TEG-ALG to obtain the
key functional polymer ALGQSI, (Scheme 1). We also pre-
pared a second polymer, ALGALD, in which 2-ethynylbenzal-
dehyde was coupled to the N3-TEG-ALG backbone via the
same click chemistry, but with no QSI attached. This was in
order to render the polymer more amphiphilic, even without
the QSI present, and thus potentially able to form nano-
particles with CIP in a manner analogous to that of ALGQSI
polymers.
For both the derivatised alginates (ALGALD and ALGQSI),
quantitative consumption of N3 groups upon completion of
the click reaction was confirmed by complete disappearance
on 2100 cm−1 peak in IR. In addition, FTIR signals at
1686 cm−1 and 2855 cm−1 for aromatic aldehyde carbonyl
stretching, 2918 cm−1 for triazole, along with triazole + amide
+ aromatic signals (7.2–8.5 ppm), –CHO signal (10 ppm) in 1H
NMR, and characteristic peaks in 13C NMR (for e.g. –CHO:
196 ppm) confirmed the successful formation of ALGALD.
Similarly, for the ALGQSI polymer, characteristic IR absorption
bands corresponding to CHvNH stretching for hydrazones
(1510 cm−1) and an intense band at 713 cm−1 for heteroatom
C–Cl vibration confirmed the successful functionalisation with
the QSI via a pH-responsive linkage. Characterisation of
ALGQSI via
1H NMR was problematic at 25 °C due to the ten-
dency for the polymers to self-assemble, leading to poorly-
resolving signals. However, using elevated temperature NMR at
70 °C in a mixture of DMSO-d6 + D2O, the triazole + amide +
aromatic signals in the range of 7.2–8.5 ppm, and ethylene
glycol peaks (3.60–3.90 ppm) from N3-TEG-NH-were apparent
alongside the alginate peaks. The successful coupling of the
QSI on the N3-PEG3-ALG polymer was further verified by
13C
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NMR, and the absence of signals corresponding to –CHO in
1H, 13C and FTIR for ALGQSI also confirmed that the reversible
hydrazone bond remained intact following synthesis and the
conditions required for characterisation, with no evident liber-
ation of ACNQ (Fig. 2).
Nanoparticle formulation and characterisation
After confirming the successful formation of the targeted
amphiphilic structures-ALGALD and ALGQSI, the next step was
to prepare self-assembled nanostructures. This was readily
accomplished by a single step nanoprecipitation in phosphate
buﬀer, owing to the amphiphilic character of the hydrophobic
(triazole + ACNQ C9 chain in ALGQSI) and the hydrophilic (algi-
nate and triethylene glycol) components. Both the polymers
formed NPs with comparable diameters and zeta potentials
(Table 1, Fig. 3A and B, Table S1, Fig. S11†). The negative zeta-
potentials of the NPs with or without CIP confirmed that their
outer exposed layer was predominantly the carboxyl-containing
alginate chains.
The in vitro drug release profiles from the NPs were evalu-
ated at pH 7.4 and 6.0 that were considered likely to be
encountered in ambient biological conditions and in an estab-
lished biofilm, respectively. Higher cumulative release of the
QSI drug from ALGQSI was observed at biofilm relevant pH 6.0
(0.5 M citrate buﬀer) than at pH 7.4 (0.1 M phosphate buﬀer),
which was attributable to the accelerated hydrazone bond clea-
vage at the lower pH (Fig. 3C). Similarly, greater release of
Scheme 1 In (A) the QSI drug-3-amino-7-chloro-2-nonylquinazolin-4(3H)-one(ACNQ) was coupled with 2-ethynylbenzaldehyde to form the
alkynyl-functional intermediate (Z)-7-chloro-3-((2-ethynylbenzylidene)amino)-2-nonylquinazolin-4(3H)-one. In (B) carboxyl groups in sodium algi-
nate were ﬁrst activated then reacted with an α,ω-amine and azide-functional triethyleneglycol to form N3-TEG-ALG, which was then ‘clicked’ (as
shown in C) with (Z)-7-chloro-3-((2-ethynylbenzylidene)amino)-2-nonylquinazolin-4(3H)-one to form the ALGQSI polymer. In (D) Ciproﬂoxacin (CIP)
was formulated into nanoparticles by an in situ nanoprecipitation process with ALGQSI.
Fig. 2 (A) 1H NMR spectra of ALGQSI at 70 °C and ALGALD at 25 °C. (B)
FT-IR spectra comparing N3-PEG3-ALG, ALGQSI and ALGALD showing
complete consumption of azide (2100 cm−1) for ALGQSI and ALGALD, and
other characteristic peaks.
Table 1 Properties of alginate-derived nanoparticles
Formulation Diametera/nm Zeta potential/mV
ALGALD 221 −65.5
ALGQSI 209 −39.7
ALGALDCIP 242 −42
ALGQSICIP 179 −44.8
a Particle size reported is the diameter at the maximum peak height in
the particle size distributions as obtained by dynamic light scattering.
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ciprofloxacin from both ALGQSI and ALGALD was observed at
pH 6.0 than at pH 7.4 (Fig. 3D). This can be attributed to the
high solubility of ciprofloxacin (pKa acid-6.16) at this pH range
overcoming it’s entrapment in the hydrophobic core along
with the protonation of –COOH in alginate, weakening the
electrostatic interaction between CIP and alginate.
In vitro eﬃcacy studies
The biofilm ECM is a major barrier to drug transport and
eﬃcacy in biofilm killing and removal. Our hypothesis was
that alginate-based nanoparticles would be advantageous in
overcoming this barrier and distributing throughout the
biofilm, especially as the net negative charges of the alginate-
derivative NPs should prevent their accumulation at the
biofilm surface. The latter problem limits the eﬃcacy of many
antimicrobial drugs, which are weakly basic and thus posi-
tively charged as they do not penetrate deeply into the biofilm
core where antibiotic resistant or tolerant bacterial subpopu-
lations are present.
Dye-labelled alginates were prepared by coupling 6-amino
fluorescein to the previously synthesised N3-TEG-ALG and the
polymers were formulated as before into ∼200 nm nano-
particles. The NPs were administered to pre-established PAO1-
N biofilms uniformly stained with SYTO64 (shown in blue in
Fig. 4). No evident penetration by the fluorescent NPs was
observed after 1 h incubation of the biofilms (fluorescein
labelled NPs in yellow). However, after 2 h, the surface layers
were partially covered with the NPs and within 24 h complete
penetration throughout the biofilm was observed. In order to
evaluate the role of alginate in determining the extent of
biofilm penetration, we also tested commercially available
fluorescent polystyrene NPs of comparable diameters (50 and
200 nm) with both +ve (commercially available) and −ve zeta
potentials (derived by reaction of commercial –NH2 terminated
polystyrene NPs with succinic acid). These NPs irrespective of
their zeta potentials or diameters (50 nm–+53.7 mV and
−32.6 mV, 200 nm–+48.4 mV and −32.5 mV) were unable to
penetrate even after 24 h and stayed mostly at the outer sur-
faces of the biofilm (Fig. 4, ESI Fig. S16†). These assays con-
firmed the ability of the modified alginate NPs to penetrate
the PAO1-N biofilms eﬀectively and to a much greater extent
than non-alginate-based NPs.
To demonstrate the impact of combination therapy, we
intended that ACNQ should act as a non-growth inhibitory adju-
vant to CIP, by impacting on the biofilm architecture to render
Fig. 3 TEM images of (A) ALGQSICIP and (B) ALGALDCIP NPs. (C)
Release proﬁle over 24 h of ACNQ from ALGQSI at pH 6.0 and 7.4. (D)
Ciproﬂoxacin release from ALGALD-CIP at pH 6.0 and 7.4.
Fig. 4 Penetration of P. aeruginosa bioﬁlms by alginate nanoparticles. In (A), confocal laser scanning microscopy (CLSM) images show penetration
of 6-amino ﬂuorescein-ALGALD, ALGALDCIP, ALGQSI and ALGQSICIP NPs over time into PAO1-N bioﬁlms stained with SYTO64 dye. The ﬂuorescein
labelled NPs are shown in yellow and the bacteria are stained blue. After incubating the bioﬁlms for 1 h no penetration is observed as evident from
the blue stained bioﬁlm. The NPs begin to penetrate after 2 h of incubation as observed by the increase in yellow ﬂuorescence from the bioﬁlm
structure. Within 24 h complete penetration to the bioﬁlm bulk is observed, evident from the 3D Z-stack of the bioﬁlm shown on the top and right
of the main image. Scale bar: 100 μm. In (B), the penetration of the diﬀerent ALG-based NPs within 24 h is quantiﬁed (bars), in contrast to the poly-
styrene (PS) NPs which are mostly present in the outer layer of the bioﬁlm (28–42 µm depth, circles joined with lines). The ﬂuorescence intensities
of the ALG NPs and polystyrene NPs are normalised to the background ﬂuorescence of the bioﬁlm stain.
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the biofilm sensitive to the killing action of the antibiotic. To
validate this, we investigated the eﬀects of ALGQSI NPs on the
growth of planktonic PAO1-N for 24 h. The presence of NPs
inflicted no adverse eﬀect on bacterial growth. Similarly, the
biofilm viability also remained unaltered upon administration
of ALGQSI NPs over 24 h (ESI Fig. S13†). We also investigated
whether the encapsulation of CIP in NPs could aﬀect its activity
by comparing the MICs of encapsulated and free CIP, which
were demonstrated to be comparable (0.2 µg mL−1) (ESI Fig. S12
and S13†). After confirming that the adjuvant was not aﬀecting
the growth or viability of PAO1-N in planktonic or biofilm
states, we evaluated the eﬀect of CIP on biofilm viability when
co-delivered with ACNQ in the alginate NPs.
PAO1-N biofilms were established for 3 days before challen-
ging with NP-delivered therapeutics (Fig. 5) followed by Live/
Dead staining. Untreated biofilms (Fig. 5A), those treated with
buﬀer (Fig. 5B) or ACNQ only (Fig. 5C) showed only live bac-
teria. When the biofilms were exposed to CIP, some evidence
of dead bacteria was obtained due to areas of red staining
within the biofilm (Fig. 5D) and treatment with the quorum
sensing inhibitor ACNQ combined with CIP resulted in
enhanced cell kill, but in ‘patchy’ domains (Fig. 5E). The most
eﬀective treatment was with ALGQSI-CIP (Fig. 5F) in which
deep penetration into the biofilm was apparent as evident
from the large and diﬀuse red staining of dead bacteria.
Further quantification of the data is shown in Fig. 5G,
including an additional formulation, ALGALD-CIP. These data
showed that administration of CIP (60 µg mL−1 – i.e. 300 times
the MIC of planktonic PAO1-N) to biofilms resulted in ∼50%
cell kill after 24 h (Fig. 5G, red bar), and no noticeable
improvement in the treatment of biofilm was observed by
administering ACNQ in solution along with CIP (Fig. 5G,
brown bar). In both the cases, the 3D images of biofilms post
treatment revealed that only the outer surfaces of the biofilms
exposed to the drugs were aﬀected whereas the bulk of the bio-
films remained unaltered (ESI Fig. S15 and S16†). This is con-
sistent with low penetration of both drugs through the
biofilm. Moreover, the formation of precipitate was observed
in the growth medium after around 4 h of ACNQ adminis-
tration. This was due to the extremely hydrophobic nature of
ACNQ making its delivery impractical without a carrier system.
The limited eﬃcacy of CIP alone in these assays, and the poor
solubility of ACNQ thus suggested that a suitable delivery
system might better penetrate the biofilm enabling more
eﬀective release of drugs in situ. However, despite evidence of
biofilm penetration by the alginate-based NPs, a formulation
of CIP with the ALGALD NPs did not cause any further
reduction in biofilm viability (Fig. 5G purple bar). However,
the combined formulation, i.e. ALGQSICIP NPs containing both
the antibiotic and ACNQ markedly reduced biofilm viability
(Fig. 5F and G, orange bar). As evident from confocal
microscopy, the bacterial viability was aﬀected throughout the
biofilm because of the deep penetration of alginate NPs and
the likely delivery of both ACNQ and CIP in a spatio-temporally
controlled manner. The viability of the biofilm was reduced to
∼19% of the original value by ALGQSICIP NPs compared to
∼50% for ALGALDCIP NPs applying the same dose of CIP
(60 μg mL−1). Furthermore, the combined eﬀect of CIP and
ACNQ was apparent over a wide concentration range for
ALGQSICIP NPs in terms of reduced biofilm viability, when
compared with the corresponding concentrations of CIP alone
(5–60 µg mL−1) (ESI Fig. S14†) Therefore, the alginate NPs
mediated eﬀective penetration and delivered a QSI-induced
increase in biofilm susceptibility to antibiotic.
Fig. 5 Representative CLSM 3D Z-stack images PAO1-N bioﬁlms after 3 days’ growth and treatment for 24 hours with, (A) no drugs, (B) ALGQSI NPs,
(C) ACNQ (4 µg mL−1) (D), CIP (60 µg mL−1) (E) a combination of QSI (4 µg mL−1) + CIP(60 µg mL−1), and (F) ALGQSICIP NPs with ACNQ(QSI)-4 µg
mL−1 and CIP-60 µg mL−1. For images B, D and F, 2D microscopy images are included alongside the 3D CLSM, with overlapped live and dead
imaged bacteria (depth proﬁles along the top and right borders). The live bacteria are depicted in green (SYTO9 dye) and the dead are shown in red
colour (propidium iodide stain). In (G) are bar charts showing viability in PAO1-N bioﬁlms quantiﬁed after treatment with diﬀerent conditions for
24 hours. The concentrations of the drugs used were CIP-60 µg mL−1, CIP (60 µg mL−1) + ACNQ(QSI) (4 µg mL−1), ALGALDCIP (CIP-60 µg mL
−1) and
ALGQSICIP (ACNQ(QSI)-4 µg mL
−1 + CIP-60 µg mL−1).
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2D keratinocyte infection model
In addition to the eﬀectiveness of the NP formulation in
killing a preformed P. aeruginosa biofilm, its ability to prevent
biofilm formation was also tested in a 2D keratinocyte skin
epidermal cell infection model. Both the empty (ALGALD) and
the NPs containing the QSI alone (ALGQSI) were added at the
time of bacterial inoculation and biofilm formation was
assessed after 20 h. Fig. 6 shows that the presence of ALGQSI
significantly reduced biofilm formation (p-value <0.0001).
However, it was apparent that the addition of the empty NPs
alone also exerted a negative impact on biofilm formation
(p-value <0.0001 for the 3 parameters) in this model. When
comparing the impact of ALGQSI and ALGAL NPS on biofilm
formation, bio-volume and average thickness but not surface
area were significantly reduced in the presence of the QSI
(p-values of 0.0105 and 0.0036 respectively; Fig. 6).
Importantly, administration of ALGQSI NPs protected the
HaCat cells to a much greater extent than the untreated layer
or those or treated with the ALGALD NPs (Fig. 6).
3D skin infection model
The eﬃcacy of the NPs on a pre-existing P. aeruginosa skin
infection was also tested. In this assay, ex vivo porcine skin
plugs were inoculated with P. aeruginosa and after 24 h of
infection, NPs were introduced and the skin incubated for a
further 24 h. The viable bacterial loads recovered from the
skin plugs were determined and the data are depicted in
Fig. 7.
Fig. 6 2D Keratinocyte Infection Model. HaCat cell monolayer infected with PAO1-N for 20 h (A) and treated with ALGQSI (B) or ALGALD (C) NPs
(Image inserts show representative PAO1-N bioﬁlms obtained). D, E & F: CLSM images of uninfected HaCat cells untreated (D), uninfected with 20 h
ALGQSI treatment (E) and uninfected with 20 h ALGALD treatment (F). In G, bar charts showing (L–R) the eﬀects of the diﬀerent treatments on PA
bioﬁlm volume, average thickness and surface area. *: Statistically signiﬁcant (p-value <0.05). The ﬁgure represents the average of four repeats.
Fig. 7 Bacterial load (log10CFU mL
−1) recovered from skin infected with
P. aeruginosa (PA) after 24 h or 48 h of incubation and/or after 24 h
treatment with ciproﬂoxacin (CIP), ALGQSI, ALGQSICIP, ALGALD,
ALGALDCIP. The bacterial inoculum is also represented. *: Statistically
signiﬁcant (p-value < 0.05). The ﬁgure depicts the average of 4
experiments.
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It is apparent from Fig. 7 that CIP alone (p-value <0.0001),
ALGALDCIP (p-value <0.0001) and ALGQSI (p-value = 0.0048)
each significantly reduced the bacterial load. However, the
combination of the QSI and CIP, when included in the alginate
nanoparticle formulation, completely cleared the infection
(p-value <0.0015).
These data together show that the combination NP thera-
peutic was the most eﬀective against the microbial commu-
nities in both 2D and 3D assays and, most importantly, in a
relevant ex vivo infected skin model. It is well established that
bacterial-biofilm centred infections are recalcitrant, chronic
and diﬃcult to eradicate with conventional antibiotic therapy,8
and that new treatment modalities are urgently needed.
P. aeruginosa biofilms are frequently associated with recurrent
respiratory tract infections in cystic fibrosis and chronic
obstructive pulmonary disease as well as diabetic wounds and
implanted medical device (e.g. catheter) associated infections.
Biofilms in general are highly tolerant to antibiotics and often
require concentrations over 1000 times higher than those
required to kill planktonic cells although newly formed biofilms
are more susceptible than mature biofilms.8 Therefore, the
need for more eﬀective treatments capable of killing established
biofilms is also paralleled by the requirement for methods to
prevent biofilm formation. Here we have shown that alginate
NPs are not only capable of penetrating and delivering an anti-
microbial agent payload deep into a P. aeruginosa biofilm but
are also, in the absence of a payload, able to reduce biofilm for-
mation in an infection model where the biofilm is allowed to
form on a keratinocyte skin cell monolayer. However, the
inclusion of a biofilm disrupting QSI, not only reduced biofilm
formation to a greater extent but also provided some protection
for the keratinocytes. In a more sophisticated ex vivo porcine
skin model, the incorporation of both an antibiotic and a QSI
within the alginate NP delivery system was required to eradicate
completely the viable bacteria. As observed for the pre-formed
biofilm, the dual action NP delivery system was far more
eﬀective than ciprofloxacin in solution, suggesting a clear
advantage of incorporating the antibiotic in a carrier. In
addition, the combined delivery system eﬀectively killed the
biofilm in situ with little apparent dispersal of the biofilm bac-
teria. This may oﬀer an additional advantage in clinical prac-
tice, in that it reduces the likelihood of bacterial aggregates
breaking away to initiate biofilm formation at new sites.
Furthermore, while the QSI ACNQ has previously been shown to
inhibit biofilm formation,40 its eﬀect on preformed biofilms
when delivered in NPs had not been shown before. Although
ACNQ has a micromolar IC50, more potent PqsR analogues with
nanomolar eﬃcacies have recently been described and may
oﬀer improved potency as antibiotic adjuvants when delivered
in NPs.23,41 Alternatively, a more rapid route to clinical testing
could be achieved by incorporating re-purposed FDA-approved
drugs such as clofoctol, an compound that acts as an antibiotic
against Gram-positive but not Gram-negative bacteria but is a
potent PqsR antagonist for P. aeruginosa.42
For the delivery system we selected alginate as the carrier
polymer, in part because alginate oligomers have previously
been shown to inhibit biofilm formation and potentiate the
action of antibiotics against P. aeruginosa.33,43 However,
P. aeruginosa strains produce heterogeneous ECMs that may
contain one or more of three diﬀerent exopolysaccharides
including alginate.44 The P. aeruginosa strain PAO1-N used in
our assays do not produce alginate containing biofilms and
therefore it would be of interest to determine the eﬃcacy of
the NP delivery system in future against the mucoid-alginate
producing P. aeruginosa strains that are frequently found in
the lungs of individuals with cystic fibrosis who are chronically
colonized by P. aeruginosa.43,44 In addition, further work will
be required to determine whether dual action NPs are capable
of eradicating P. aeruginosa biofilms in murine infection
models and can be formulated for the treatment and preven-
tion and treatment of chronic wounds and medical device
associated infections. The advantages of a nanoparticulate for-
mulation in this setting are the ability to incorporate multiple
agents which could in principle be released by a range of
in situ disease-related triggers, such as inflammatory oxidative
stress45 in addition to local pH, thus enabling tuning of
therapy to particular wound conditions. Finally, it would be of
interest to evaluate the eﬀects of functionality, charge,
polymer/nanoparticle size and architecture systematically in
bacterial recognition, biofilm penetration and therapeutic
delivery.46–49 It is well-established that natural nanoparticu-
lates such as viruses can penetrate through many biological
barriers, and biomimicry of bacteriophage structural features
might in future allow development of highly active synthetic
NPs which exhibit functional mimicry and anti-bacterial
action also.
Conclusions
In this study we have shown that alginate biopolymers can
be modified to contain a responsive linker to the QSI ACNQ,
and induced to self-assemble in the presence of an anti-
biotic, ciprofloxacin, to generate well-defined nanoparticles.
These materials were able to release both the encapsulated
antibiotic and the conjugated QSI in response to pH values
expected in bacterial biofilms. When evaluated for eﬃcacy
against P. aeruginosa biofilms the nanoparticles were more
eﬀective in bacterial killing than the antibiotic alone, and
the extent of cell killing was retained deep into the biofilm
layer. The most significant data related to the activity of the
nanoparticles in 2D keratinocyte and 3D ex vivo skin infec-
tion models. The alginate NPs showed some protective
activity against P. aeruginosa infection in keratinocytes even
in the absence of antibiotic, but the full combination thera-
peutic system completely cleared the infection in the 3D
ex vivo skin model. In summary, the results demonstrate
considerable promise for nanoparticle combination thera-
peutics, in the prevention of biofilm formation, in the
reduction in biofilm load and through enhanced cell killing
in established biofilms of the important ESKAPE pathogen
P. aeruginosa.
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